Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches

John H. Strickler; Christina Wu; Tanios Bekaii-Saab

doi:10.1016/j.ctrv.2017.08.006

Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches

John H. Strickler, Christina Wu, Tanios Bekaii-Saab

Hematology/Oncology

Research output: Contribution to journal › Review article › peer-review

31 Scopus citations

Abstract

Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7–10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the general population of patients with mCRC, patients with BRAF-mutant mCRC continue to have poor response to most systemic therapies, and prognosis remains poor. There is a substantial unmet need for novel therapeutic strategies to treat patients with BRAF-mutant mCRC. This review outlines the epidemiology, molecular pathogenesis, prognosis, and mechanisms of treatment resistance of BRAF-mutated CRC. Additionally, this review highlights novel therapeutic strategies aimed at enhancing response and improving outcomes.

Original language	English (US)
Pages (from-to)	109-119
Number of pages	11
Journal	Cancer Treatment Reviews
Volume	60
DOIs	https://doi.org/10.1016/j.ctrv.2017.08.006
State	Published - Nov 2017

Keywords

BRAF
Colorectal cancer
Targeted therapy

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.ctrv.2017.08.006

Cite this

@article{c3e408f6c45441918ae9fcf1ad8ed291,

title = "Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches",

abstract = "Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7–10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the general population of patients with mCRC, patients with BRAF-mutant mCRC continue to have poor response to most systemic therapies, and prognosis remains poor. There is a substantial unmet need for novel therapeutic strategies to treat patients with BRAF-mutant mCRC. This review outlines the epidemiology, molecular pathogenesis, prognosis, and mechanisms of treatment resistance of BRAF-mutated CRC. Additionally, this review highlights novel therapeutic strategies aimed at enhancing response and improving outcomes.",

keywords = "BRAF, Colorectal cancer, Targeted therapy",

author = "Strickler, {John H.} and Christina Wu and Tanios Bekaii-Saab",

note = "Publisher Copyright: {\textcopyright} 2017 The Author(s)",

year = "2017",

month = nov,

doi = "10.1016/j.ctrv.2017.08.006",

language = "English (US)",

volume = "60",

pages = "109--119",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Targeting BRAF in metastatic colorectal cancer

T2 - Maximizing molecular approaches

AU - Strickler, John H.

AU - Wu, Christina

AU - Bekaii-Saab, Tanios

PY - 2017/11

Y1 - 2017/11

N2 - Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7–10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the general population of patients with mCRC, patients with BRAF-mutant mCRC continue to have poor response to most systemic therapies, and prognosis remains poor. There is a substantial unmet need for novel therapeutic strategies to treat patients with BRAF-mutant mCRC. This review outlines the epidemiology, molecular pathogenesis, prognosis, and mechanisms of treatment resistance of BRAF-mutated CRC. Additionally, this review highlights novel therapeutic strategies aimed at enhancing response and improving outcomes.

AB - Oncogenic mutations in B-type Raf kinase (BRAF) occur in 7–10% of metastatic colorectal cancers (mCRC). Despite recent improvements in survival in the general population of patients with mCRC, patients with BRAF-mutant mCRC continue to have poor response to most systemic therapies, and prognosis remains poor. There is a substantial unmet need for novel therapeutic strategies to treat patients with BRAF-mutant mCRC. This review outlines the epidemiology, molecular pathogenesis, prognosis, and mechanisms of treatment resistance of BRAF-mutated CRC. Additionally, this review highlights novel therapeutic strategies aimed at enhancing response and improving outcomes.

KW - BRAF

KW - Colorectal cancer

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85029820079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029820079&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2017.08.006

DO - 10.1016/j.ctrv.2017.08.006

M3 - Review article

C2 - 28946014

AN - SCOPUS:85029820079

SN - 0305-7372

VL - 60

SP - 109

EP - 119

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

ER -

Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this